Innovative Partnership to Transform Cell and Gene Therapy
Cellular Origins, a TTP Company, and Fresenius Kabi, an operating company of Fresenius, have entered into a significant development agreement. This collaboration merges the expertise of both organizations in the field of cell and gene therapies (CGTs) with a clear goal: to revolutionize the manufacturing processes through automation. The agreement is structured to digitally and physically integrate Fresenius Kabi's advanced cell therapy processing technologies within Cellular Origins’ robotic manufacturing platform, known as Constellation.
Goals of the Collaboration
The primary goal of this partnership is to provide cell therapy developers with a means to scale their manufacturing capabilities while utilizing their preferred processing tools. As both companies embark on this joint venture, they aim to facilitate the production of cell-based therapies that can meet increasing global demands.
Cellular Origins focuses on producing scalable, efficient, and cost-effective cell and gene therapies. By leveraging its Constellation automation platform, the company is set to enhance this space. Fresenius Kabi, well-known for its expertise in critical care and advanced health technologies, will contribute its profound knowledge of cell therapy systems, targeting seamless integration with the Constellation platform.
Technical Integration of Advanced Technologies
The initial focus of the collaboration will be on Fresenius Kabi’s Cue Cell Processing System, a well-engineered technology designed for automated small-volume cell processing. The partnership aims at creating a fully automated system wherein the Cue will enable robotic consumable transport, installation, and operation, operating autonomously around the clock.
Features of the Cue Cell Processing System
The Cue Cell Processing System’s design supports critical applications such as final formulations and culture media exchanges with precision and reliability. Its flexible framework allows for integration into existing workflows, making it an ideal candidate for Cellular Origins as they work to amplify the capabilities of their manufacturing platform.
This collaboration seeks to address some of the most pressing challenges in the production of advanced therapies by eliminating the need for extensive process redevelopment. As a result, they aim to significantly increase production space efficiency while minimizing the number of personnel required.
Long-term Vision for Collaboration
Beyond the initial integration, the collaboration will also explore integrating additional Fresenius Kabi technologies, including their broader cell therapy portfolio. This forward-thinking approach will ensure that they remain at the forefront of CGT advancements.
Leadership Perspectives on the Partnership
Dr. Edwin Stone, CEO of Cellular Origins, has expressed the importance of robust collaborations in advancing the industry. He emphasized the need for automation and the right tools for producing cell therapies, which this partnership seeks to support. Similarly, Dr. Christian Hauer, President MedTech at Fresenius Kabi, noted that automation is vital to overcoming challenges in research and manufacturing processes.
Both companies are driven by a shared mission: to deliver life-saving therapies to patients at a faster pace and at a lower cost, leveraging their combined resources and expertise.
About Cellular Origins and Fresenius Kabi
Cellular Origins is dedicated to providing scalable and efficient manufacturing solutions for the cell and gene therapy sector. The company aims to bridge the gap between innovative therapeutic development and the manufacturing capabilities that support widespread access to these essential treatments.
Fresenius Kabi, a global health care powerhouse, strives to make high-quality and life-saving medical products accessible. With a vast employee base and operations in numerous countries, they focus on providing essential therapies that improve patient outcomes. Their dedication to advancing medical technology positions them as a leader in the health care industry.
Frequently Asked Questions
What is the main goal of the partnership between Cellular Origins and Fresenius Kabi?
The collaboration aims to enhance the scalability of cell therapy manufacturing processes using automation and advanced integration of processing technologies.
What technologies will be integrated under this partnership?
Initially, the focus will be on integrating the Cue Cell Processing System from Fresenius Kabi into Cellular Origins' Constellation platform.
Why is automation important for cell and gene therapy manufacturing?
Automation helps reduce human error, increases efficiency, and allows for 24/7 manufacturing capabilities, essential for meeting global demand.
What does the future hold for this collaboration?
Both companies plan to explore broader integration opportunities with Fresenius Kabi’s cell therapy technology portfolio to further enhance manufacturing capabilities.
How do Cellular Origins and Fresenius Kabi impact patient care?
By streamlining therapies' production processes, they aim to make innovative treatments more widely available and affordable for patients.
